PROSTVAC(TM) - further data presented
In February 2009, the first detailed data on PROSTVAC(TM) were presented at the international cancer congress, 2009 Genitourinary Cancers Symposium in Orlando, Florida.
The data from three different studies once again confirms the excellent safety and efficacy results previously reported, and they support the further investigation of the vaccine in patients suffering from advanced prostate cancer. The data also indicates that PROSTVAC(TM) may be used in a larger patient group.
MVA-BN(R)-HER2 - data from ongoing studies reported. New studies to be initiated.
In February 2009, Bavarian Nordic reported data from its Phase I/II studies with the therapeutic breast cancer vaccine candidate, MVA-BN(R)-HER2. The data showed that the study met its primary endpoint with regards to safety and by showing an immune response.
Oxford BioMedica - patent infringement suit continues
The patent infringement suit that was filed against Oxford BioMedica in 2008 continues. In January 2009, Bavarian Nordic filed a new complaint after that the Judge, for procedural reasons, dismissed the first complaint. If the court eventually should decide to dismiss the suit this decision will bear no influence on the substance of the patent case. It only influences the timing of the start of the infringement case.
Changes in management
Executive Vice President, Commercial Affairs, Nicolai Buhl Andersen has
chosen to resign from his position in Bavarian Nordic as of 1 May 2009 to
work at Coloplast where he also worked previously. Steen Vangsgaard has been
appointed as his successor as from 27 March 2009. Steen Vangsgaard holds an
|SOURCE Bavarian Nordic A/S|
Copyright©2009 PR Newswire.
All rights reserved